Clinical Research Papers:

Expression and clinicopathological significance of FSIP1 in breast cancer

Hao Zhang, Minna Luo, Zining Jin, Dan Wang, Ming Sun, Xinhan Zhao _, Zuowei Zhao, Haixin Lei, Man Li and Caigang Liu

PDF  |  HTML  |  How to cite

Oncotarget. 2015; 6:10658-10666. https://doi.org/10.18632/oncotarget.3381

Metrics: PDF 1942 views  |   HTML 2410 views  |   ?  


Hao Zhang1,*, Minna Luo2,*, Zining Jin3,*, Dan Wang1, Ming Sun4, Xinhan Zhao2, Zuowei Zhao1, Haixin Lei5, Man Li1, Caigang Liu1

1Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Hospital of Dalian Medical University, Dalian, China

2Department of Oncology, The First Affiliated Hospital, Xi’an Jiaotong University, Xi’an, China

3Department of Breast surgery, The First Hospital of China Medical University, Shenyang, China

4Shengjing Hospital, China Medical University, Shenyang, China

5Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China

*These authors have contributed equally to this work

Correspondence to:

Man Li, e-mail: [email protected]

Haixin Lei, e-mail: [email protected]

Caigang Liu, e-mail: [email protected]

Keywords: breast cancer, prognosis, metastasis, FSIP1

Received: December 09, 2014     Accepted: February 14, 2015     Published: March 25, 2015


Aim: To investigate the clinicopathological significance of the expression of fibrous sheath interacting protein 1 (FSIP1) in breast cancer, serum samples, and wound fluid from patients with breast cancer.

Methods: Wound fluid and serum samples from female patients with primary breast cancer, recurrent and metastatic breast cancer, and benign tumors were analyzed for FSIP1 expression using ELISA. 286 paraffin-embedded surgical specimens from breast cancer patients with at least 5 years of follow-up were included for FSIP1 expression assay using immunohistochemistry.

Results: Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001). Strong correlation was observed between FSIP1 expression and human epidermal growth factor receptor 2 (Her-2) or Ki67 expression in breast cancer (p = 0.027 and 0.002, respectively). Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003). Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).

Conclusion: FSIP1 may play an important role in the tumorigenesis and invasion of breast cancer and is a potential biomarker for breast cancer diagnosis or prognosis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3381